期刊文献+

大黄减轻维持性血液透析患者静脉铁剂诱导的微炎症反应 被引量:2

Effects of rhubarb on microinflammation induced by intravenous iron in maintenance honodialysis patients
下载PDF
导出
摘要 目的探讨大黄对维持性血液透析(MHD)患者静脉铁剂诱导的微炎症反应的影响。方法选择在我院血液净化中心行MHD治疗的患者50例,随机分为静脉铁剂治疗组(A组)和静脉铁剂+大黄治疗组(B组)。B组给予大黄泡水饮服8周。分别于治疗前后检测各组患者血红蛋白(Hb)、红细胞压积(Hct)、血清铁(SI)、铁蛋白(SF)、转铁蛋白饱和度(TSAT),C反应蛋白(CRP),肿瘤坏死因子α(TNF-α)、白细胞介素(IL)-1β、11710等。结果治疗8周后,A组和B组Hb、Hct、SI、SF、TSAT、CRP、TNF-α、IL-1β较治疗前升高;B组CRP、TNF-α、IL-1β均较A组降低(P〈0.01或P〈0.05);2组IL-10水平差异无统计学意义(P〉0.05)。结论大黄可以减轻静脉铁剂诱导的微炎症反应。 Objective To investigate the effects of rhubarb against microinflammation induced by intravenous iron in maintenance hemodialysis(MHD)patients. Methods Forty-nine MHD patients were randomly allocated to intravenous iron group(group A, n = 24), and intravenous iron plus rhubarb group (group B,n = 25). Patients in group B were administered with infused decotion of rhubarb for 8 weeks. The blood levels of hemoglobin (Hb), hematocrit (Hct), serum iron (SI), serulnferritin (SF), transferring saturation (TAST),C-reactive protein (CRP), tumor necrosis factor-α(TNF-α), interleu- kin (IL)-1β and IL-10 were measured before and after the treatment. Results After treatment, the levels of Hb, Hct,SI,SF,TSAT,CRP, TNF-α,IL-1β in both groups A and B were higher than those before the treatment(P〈0. 05 or P〈0. 01, respectively). The levels of CRP, TNF-α, IL-1β in group B were lower than those in group A(P〈0.05 or P〈0.01, respectively). There was no significant difference in the levels of IL-10 amongst two groups. Conclusion Rhubarb can alleviate microinflammation induced by intravenous iron in MHD patients.
作者 张玉新 陈新
出处 《临床肾脏病杂志》 2010年第4期188-190,共3页 Journal Of Clinical Nephrology
关键词 大黄 肾透析 贫血 缺铁性 Rhubarb Renal dialysis Anemia, iron-deficiency
  • 相关文献

参考文献9

二级参考文献32

共引文献83

同被引文献51

  • 1冯利平,张玲,钟玲,朱冬菊,刘玲.口服维生素E对维持性血液透析患者血清几种炎症因子水平的影响[J].第三军医大学学报,2007,29(8):733-735. 被引量:8
  • 2梁静,曹灵.慢性肾衰竭微炎症状态的研究进展[J].中国中西医结合肾病杂志,2007,8(7):428-430. 被引量:16
  • 3Eckardt KU, ScherhagA, MacdougallIC, et al. Left? ventricular? geometry? predicts cardiovascular outcomes associated with ane- mia correction in CKD. J Am Soc Nephroh 2009,20 (12):2651- 2660.
  • 4Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: An overview. Am J Health Syst Pharm,2007,64(13,Suppl 8) : S.3-S7.
  • 5NKF-K/DOQI . Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease~ 2007 up- date of hemoglobin target. Am J Kidney Dis,2007,50:474.
  • 6Martin Wagner, David Ansell, David M Kent, et al. Predicting mrotality in incident dialysis patients: An analysis of the united kingdom renal registry. Am J Kidney Dis, 2011,57(6) : 894-902.
  • 7Merino A, Nogueras S, Buendia P, et al. Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol, 2008,161: 83-88.
  • 8Gupta A, Zhuo J, Zha J,et al. Effect of different intravenous i- ron preparations on lymphocyte intracellular reactive oxygen spe- cies generation and subpopulation survival. BMC Nephrol,2010, 17:11-16.
  • 9Merle U, Fein E, Gehrke SG, et al. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology, 2007,148 : 2663-2668.
  • 10Feldman H I,Joffe M, Robinson B, et al. Administration of paren- teral iron and mortality among hemodialysis patients. J Am Soc Nephrol, 2004,15 : 1623-1-632.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部